虽然青光眼降眼压药物取得了重大进展，但手术治疗仍是重要手段。
Though further progress has been maken in medication of decreasing intraocular pressure, surgery is still the main methods in the treatment of glaucoma.
青光眼视神经损害的主要危险因素是眼压升高，降眼压药物治疗仍为首选。
The main risk factor for of optic nerve lesion glaucoma is the rising of intraocular tension. Treatment with drugs to lower intraocular tension is still the first choice.
所有患者经降眼压药物治疗及调整激素用量或停用激素处理后，眼压均控制在正常范围。
After using IOP-lowering drugs and adjusting or cessation of glucocorticoid eyedrops, the elevated IOP in all patients was controlled within normal limits.
目的：观察用降眼压药物而眼压不能控制的病人，加用拉坦前列素滴眼液治疗的临床疗效。
AIM: To observe the clinical effect of latanoprost eye drops in patients who intraocular pressure (IOP) was uncontrolled by decreases IOP drugs.
如果在增加一种降眼压药物的情况下无法控制眼压，应该建议患者去青光眼专家处就诊，因为有些患者需要手术治疗。
If the IOP cannot be managed with the addition of glaucoma medications, subspecialty care from a glaucoma specialist should be sought as some patients may go on to require surgical intervention.
结论：对用降眼压药物而眼压不能控制的病人，加用拉坦前列素滴眼液可以有效的控制眼压，防止青光眼对视功能的进一步损伤。
CONCLUSION: by adding latanoprost can effectively control IOP in patients whose IOP was uncontrolled by decreases IOP drugs and prevent glaucoma from further damaging the visual function.
现就目前正在使用的抗青光眼药物做一综述性回顾并介绍正在研究开发的抗青光眼新药的药效及降眼压机制。
The aims of this article are to provide an overview of current drug management of glaucoma and introduce new drug being investigated about pharmacodynamic action and mechanism.
现就目前正在使用的抗青光眼药物做一综述性回顾并介绍正在研究开发的抗青光眼新药的药效及降眼压机制。
The aims of this article are to provide an overview of current drug management of glaucoma and introduce new drug being investigated about pharmacodynamic action and mechanism.
应用推荐